Lapatinib for Advanced or Metastatic Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,419 · see citing works

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125 · see citing works

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,016 · see citing works

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Blackwell, K., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G. W., Koehler, M. T., Ellis, C. E., Casey, M., Vukelja, S. J., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 940 · see citing works

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

Cameron, D., Casey, M., Press, M. F., Lindquist, D. L., Pieńkowski, T., Romieu, C. G., Chan, S. Y. T., Jagiełło-Gruszfeld, A., Kaufman, B., Crown, J. P., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794 · see citing works

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Čufer, T., de Jongh, F. E., Maartense, E., Zielinski, C. C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 674 · see citing works

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664 · see citing works

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619 · see citing works

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Leo, A. D., Gómez, H., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S., Koehler, M. T., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 417 · see citing works

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

Clayton, A., Danson, S. J., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 384 · see citing works

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

MEDINA, P., & Goodin, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377 · see citing works

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350 · see citing works

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Cameron, D., Casey, M., Oliva, C., Newstat, B. O., Imwalle, B., & Geyer, C. E. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0181 · Cited by 301 · see citing works

Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy

Pegram, M. D., Pauletti, G. M., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 263 · see citing works

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

Polli, J. W., Olson, K. L., Chism, J. P., John‐Williams, L. S., Yeager, R. L., Woodard, S. M., Otto, V., Castellino, S., & Thiel-Demby, V. E. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024646 · Cited by 256 · see citing works

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

Xia, W., Liu, L.-H., Ho, P. T. C., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253 · see citing works

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Čufer, T., Maartense, E., de Jongh, F. D., Baumann, K., Bischoff, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.021 · Cited by 198 · see citing works

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

Koch, K. M., Reddy, N. J., Cohen, R. B., Lewis, N. L., Whitehead, B. P., Mackay, K., Stead, A. G., Beelen, A. P., & Lewis, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3285 · Cited by 138 · see citing works

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

Teng, W.-C., Oh, J. W., New, L. S., Wahlin, M. D., Nelson, S. D., Ho, H. K., & Chan, E. C. Y. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065839 · Cited by 119 · see citing works

Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., Aura, C. M., de Azambuja, E., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s3-3 · Cited by 116 · see citing works

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Burris, H. A., Taylor, C. W., Jones, S. F., Koch, K. M., Versola, M., Arya, N., Fleming, R. A., Smith, D. A., Pandite, L. N., Spector, N. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0369 · Cited by 99 · see citing works

Advanced breast cancer: diagnosis and treatment

Macbeth, F. R., Champion, A. E., Bennett, A. B., Francis, K. L., Collins, E. C., Berendse, S., Cleves, A., Coles, B., Willis, S., Welton, N. J., et al. (2008) · Bristol Research (University of Bristol) · Cited by 87 · see citing works

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer

Capri, G., Chang, J., Chen, S.-C., Conte, P., Cwiertka, K., Jérusalem, G., Jiang, Z., Johnston, S. R. D., Kaufman, B., Link, J. S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp373 · Cited by 84 · see citing works

Delivery of a Healthy Baby After First-Trimester Maternal Exposure to Lapatinib

Kelly, H., Graham, M. L., Humes, E., Dorflinger, L. J., Boggess, K., O’Neil, B. H., Harris, J., Spector, N. L., & Dees, E. C. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.048 · Cited by 69 · see citing works

Dual HER2-targeted approaches in HER2-positive breast cancer

Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64 · see citing works

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis

Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., Oyee, J., Blundell, M., Davis, H., Armstrong, A. C., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15420 · Cited by 63 · see citing works

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

Smith, D. A., Koch, K. M., Arya, N., Bowen, C. J., Herendeen, J. M., & Beelen, A. P. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03370.x · Cited by 63 · see citing works

Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS)

Bai, F., Freeman, B. B., Fraga, C. H., Fouladi, M., & Stewart, C. F. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.11.044 · Cited by 57 · see citing works

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan

Midgley, R. S., Kerr, R. S., Flaherty, K. T., Stevenson, J. P., Pratap, S., Koch, K. M., Smith, D. A., Versola, M., Fleming, R. A., Ward, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm366 · Cited by 56 · see citing works

Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid

Stemmler, H., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.1525 · Cited by 28 · see citing works

Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival

Stemmler, H., Kahlert, S., Siekiera, W., Untch, M., Heinrich, B., & Heinemann, V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1568 · Cited by 9 · see citing works

Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.

Johnston, S. R. D., Gelmon, K. A., Pivot, X. B., Gradishar, W., Conner, A., Kothari, D., Legenne, P., Leigh, M., O’Rourke, L., & Parikh, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps105 · Cited by 1 · see citing works

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism

Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216677 · Cited by 204 · see citing works

Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents

Doostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., & Dadashpour, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01607-9 · Cited by 207 · see citing works

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136 · see citing works

Recent strategies to overcome breast cancer resistance

Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N., & Torchilin, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104351 · Cited by 100 · see citing works

Adherence to targeted oral anticancer medications.

Geynisman, D. M., & Wickersham, K. E. (2013) · PubMed · Cited by 92 · see citing works

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics

Le, B. T., Raguraman, P., Kosbar, T. R., Fletcher, S., Wilton, S. D., & Veedu, R. N. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.007 · Cited by 91 · see citing works

Combinatorial therapy discovery using mixed integer linear programming

Pang, K., Wan, Y., Choi, W. T.-S., Donehower, L. A., Sun, J., Pant, D. K., & Liu, Z. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu046 · Cited by 87 · see citing works

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

de Wit, D., Guchelaar, H., den Hartigh, J., Gelderblom, H. A. J., & van Erp, N. P. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.007 · Cited by 84 · see citing works

Histology-agnostic drug development — considering issues beyond the tissue

Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 81 · see citing works

Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance

Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77 · see citing works

Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities

Ezzati, S., Salib, S., Balasubramaniam, M., & Aboud, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042316 · Cited by 70 · see citing works

Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?

Hatoum, D., & McGowan, E. M. (2015) · BioMed Research International · doi:10.1155/2015/548436 · Cited by 65 · see citing works

Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors

Hu, S., Xie, G., Zhang, D. X., Davis, C. B., Long, W. S., Hu, Y., Wang, F., Kang, X., Tan, F., Ding, L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.067 · Cited by 60 · see citing works

Lapatinib Induced Suicidal Death of Human Erythrocytes

Zierle, J., Bissinger, R., Egler, J., & Lang, F. J. W. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438583 · Cited by 56 · see citing works

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

Serritella, A. V., Strohbehn, G. W., Goldstein, D. A., Lichter, A. S., & Ratain, M. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1853 · Cited by 55 · see citing works

Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis

Huang, X., Yan, X., Zhang, Q., Hong, P., Zhang, W., Liu, Y.-P., Xu, W. W., Li, B., & He, Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.024 · Cited by 55 · see citing works

Co-targeting estrogen receptor and HER2 pathways in breast cancer

Mehta, A., & Tripathy, D. (2013) · The Breast · doi:10.1016/j.breast.2013.09.006 · Cited by 54 · see citing works

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents

Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 53 · see citing works

Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations

Vieira, T. F., Magalhães, R. P., Simões, M. V., & Sousa, S. F. (2022) · Antibiotics · doi:10.3390/antibiotics11020185 · Cited by 50 · see citing works

Paclitaxel for breast cancer therapy: A review on effective drug combination modalities and nano drug delivery platforms

Zenjanab, M. K., Alimohammadvand, S., Doustmihan, A., Kianian, S., Oskouei, B. S., Mazloomi, M., Akbari, M., & Jahanban‐Esfahlan, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105567 · Cited by 50 · see citing works

HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?

Martin, V., Cappuzzo, F., Mazzucchelli, L., & Frattini, M. (2014) · Future Oncology · doi:10.2217/fon.14.19 · Cited by 48 · see citing works

A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms

Nagy, A., Börzsei, D., Hoffmann, A., Török, S., Veszelka, M., Almási, N., Varga, C., & Szabó, R. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07574-0 · Cited by 45 · see citing works

EGFR trafficking: effect of dimerization, dynamics, and mutation

Schultz, D. F., Billadeau, D. D., & Jois, S. D. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258371 · Cited by 46 · see citing works

Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice

Dailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 38 · see citing works

The Story of EGFR: From Signaling Pathways to a Potent Anticancer Target

Ramani, S., Samant, S., & Manohar, S. M. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0343 · Cited by 32 · see citing works

circRNAs in drug resistance of breast cancer

Mısır, S., Yaman, S. Ö., Petrović, N., Sümer, C., Hepokur, C., & Aliyazıcıoğlu, Y. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.027547 · Cited by 31 · see citing works

Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

Nakano-Tateno, T., Lau, K. J., Wang, J. Z., McMahon, C., Kawakami, Y., Tateno, T., & Araki, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624686 · Cited by 30 · see citing works

Impact of the Cancer Cell Secretome in Driving Breast Cancer Progression

Zahari, S., Syafruddin, S. E., & Mohtar, M. A. (2023) · Cancers · doi:10.3390/cancers15092653 · Cited by 29 · see citing works

Therapeutic significance of molecular hybrids for breast cancer research and treatment

Shagufta, & Ahmad, I. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00356b · Cited by 27 · see citing works

2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76

Singhal, J., Chikara, S., Horne, D. A., Salgia, R., Awasthi, S., & Singhal, S. S. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22894 · Cited by 26 · see citing works

A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas

Karavasilis, V., Kotoula, V., Pentheroudakis, G. E., Televantou, D., Lambaki, S., Chrisafi, S., Bobos, M., & Fountzilas, G. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6812-z · Cited by 26 · see citing works

Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies

Romaniuk-Drapała, A., Totoń, E., Taube, M., Idzik, M., Rubiś, B., & Lisiak, N. (2024) · Cancers · doi:10.3390/cancers16132481 · Cited by 27 · see citing works

In-silico studies of glutathione peroxidase4 activators as candidate for multiple sclerosis management

Alameen, A. A., Abdalla, M., Alshibl, H. M., AlOthman, M., Alkhulaifi, M. M., Mirgany, T. O., & Elsayim, R. (2022) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2022.101554 · Cited by 24 · see citing works

Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer

Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 24 · see citing works

STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies

Godugu, D., Chilamakuri, R., & Agarwal, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189461 · Cited by 23 · see citing works

Emerging EGFR antagonists for breast cancer

Lluch, A. M., Eroles, P., & Fidalgo, J. A. P. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.903919 · Cited by 23 · see citing works

Personalized treatment approach for HER2-positive metastatic breast cancer

Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 24 · see citing works

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

Narayan, V., Mamtani, R., O’Keefe, S. J., Guzzo, T. J., Malkowicz, S. B., & Vaughn, D. J. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.405 · Cited by 23 · see citing works

Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study

Yu, Z. Y., Ye, X., Liu, H., Li, H., Hao, X., Zhang, J., Kou, F., Wang, Z., Wei, H., Gao, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893966 · Cited by 22 · see citing works

A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer

Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 21 · see citing works

EGFR inhibitors across generations: Progress, challenges, and future directions

Deshmukh, V. G., Sapkal, S. B., Gadekar, S. S., & Deshmukh, V. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142326 · Cited by 19 · see citing works

A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib

Singh, N., Chakravarti, R., Das, A., Gupta, S., Ghosh, D., & Datta, P. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00283 · Cited by 16 · see citing works

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

Gameiro, A., Almeida, F., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030346 · Cited by 14 · see citing works

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma

Gameiro, A., Urbano, A. C., & Ferreira, F. (2021) · Veterinary Sciences · doi:10.3390/vetsci8080164 · Cited by 14 · see citing works

Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations.

Saremi, S. S., Nikpoor, A., Sadri, K., Mehrabian, A., Karimi, M., Mansouri, A., Jafari, M., & Badiee, A. (2021) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2021.112012 · Cited by 12 · see citing works

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro

Leis‐Filho, A. F., Lainetti, P. D. F., Kobayashi, P. E., Fonseca‐Alves, C. E., & Amorim, R. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060897 · Cited by 12 · see citing works

Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer

Singh, N., Reddy, K. P., Das, P., Kishor, B. K., & Datta, P. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104315 · Cited by 12 · see citing works

Halogen‐based quinazolin‐4(3H)‐one derivatives as MCF‐7 breast cancer inhibitors: Current developments and structure–activity relationship

Upadhyay, R., Tandel, P. K., & Patel, A. B. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400740 · Cited by 12 · see citing works

Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis

Walker, R. R., Patel, J. R., Gupta, A., Davidson, A. M., Williams, C. C., Payton‐Stewart, F., Boué, S. M., Burow, M. E., Khupse, R. S., & Tilghman, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052887 · Cited by 12 · see citing works

Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction

Olszewski, M., Maciejewska, N., Kallingal, A., Chylewska, A., Dąbrowska, A., Biedulska, M., Makowski, M., Padrón, J. M., & Bagiński, M. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2302920 · Cited by 11 · see citing works

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study

Xu, B., Hu, X., Zheng, H. Y., Wang, X., Zhang, Q., Cui, S., Liu, D., Liao, N., Luo, R., Sun, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9331 · Cited by 11 · see citing works

Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials

Mangla, B., Mittal, P., Kumar, P., & Aggarwal, G. (2024) · Medical Oncology · doi:10.1007/s12032-024-02414-5 · Cited by 12 · see citing works

Virtual Screening to Identify Novel Inhibitors of Pan ERBB Family of Proteins from Natural Products with Known Anti-tumorigenic Properties

Ahammad, I., Sarker, M. R. I., Khan, A. M., Islam, S., & Hossain, M. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09992-3 · Cited by 9 · see citing works

Targeted Therapies Against Growth Factor Signaling in Breast Cancer

Du, J., Yu, Y., Zhan, J., & Zhang, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_6 · Cited by 8 · see citing works

Bringing Cancer Serological Diagnosis to a New Level: Focusing on HER2, Protein Ectodomain Shedding and Neoepitope Technology

Wang, J., Willumsen, N., Zheng, Q., Xue, Y. W., Karsdal, M. A., & Bay‐Jensen, A. (2012) · Future Oncology · doi:10.2217/fon.12.161 · Cited by 8 · see citing works

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8 · see citing works

Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions

Soleja, M., & Rimawi, M. F. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.005 · Cited by 7 · see citing works

Gold-capsuled polymeric nanomedicine for synergistic breast cancer photo-chemotherapy

Kaur, N., Puppala, E. R., Srivastava, R., Naidu, V. G. M., & Shanavas, A. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05640-y · Cited by 7 · see citing works

Targeted Therapies in Cancer Treatment

Cavalcanti, I. D. L., & Soares, J. C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-68334-4_5 · Cited by 7 · see citing works

Biomarker-driven drug repurposing for NAFLD-associated hepatocellular carcinoma using machine learning integrated ensemble feature selection

Ghosh, S., Mandal, S. D., & Thakur, S. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1522401 · Cited by 6 · see citing works

Leveraging computational approaches in identifying novel HER-2 + breast cancer potential therapeutics: integrating virtual screening and molecular dynamics simulation

Bolaji, O. Q., Adelusi, T. I., Ojo, T. O., Boyenle, I. D., Oyedele, A.-Q. K., Ogunjobi, T. T., Oyaronbi, A. O., Ayoola, S. O., & Ogunlana, A. T. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00748-5 · Cited by 6 · see citing works

Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report

Zhou, L. Q., Ren, Y., Wang, X., Miao, D.-L., Lizaso, A., Li, H., Han‐Zhang, H., Qian, J., & Yang, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s206732 · Cited by 6 · see citing works

Design and Synthesis of Potent Anticancer Agents Using Coumarin‐Quinazolinone Based Scaffolds: Exploration of ADME Properties and Molecular Docking Studies

Babagond, V., Katagi, K. S., Akki, M., Reddy, D. S., Shanavaz, H., Jaggal, A., & Soumyashree, D. K. (2024) · ChemistrySelect · doi:10.1002/slct.202400435 · Cited by 6 · see citing works

Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients

Koch, K. M., Ferron‐Brady, G., Lemmon, C., Cartee, L., Hollyfield, H., D'amelio, A. M., Piepszak, A. M., Swaby, R. F., Curran, D. W., & Arya, N. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.139 · Cited by 6 · see citing works

Identification of Lapatinib Derivatives and Analogs to Control Metastatic Breast Cancer-specific to South Asian Population-a Pharmacogenomic Approach

Vyshnavi, A. M. H., & Namboori, P. K. K. (2021) · WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE · doi:10.37394/23208.2021.18.6 · Cited by 6 · see citing works

Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies

Gupta, M. K., Gouda, G., & Vadde, R. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053419 · Cited by 5 · see citing works

Effect of Triton X-100 on the Electrochemical Behavior of Hydrophobic Lapatinib Used in the Treatment of Breast Cancer: A First Electroanalytical Study

Aksöz, B. E., & Dogan‐Topal, B. (2021) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ac0ec3 · Cited by 5 · see citing works

Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation

Marverti, G., Moschella, M. G., Belardo, A., Lamesta, M., Mercanile, G., Tagliazucchi, L., Aiello, D., Venturelli, A., Illuminati, D., Guerrini, R., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1477318 · Cited by 5 · see citing works

Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient

Pizzuti, L., Sergi, D., Barba, M., & Vici, P. (2013) · Tumori Journal · doi:10.1177/030089161309900332 · Cited by 5 · see citing works

A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database

Zhou, Y., Gong, J., Deng, X., Shen, L., Ge, A., Fan, H., Ling, J., Wu, S., & Liu, L. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2471515 · Cited by 4 · see citing works

Neuroinflammation as a Central Mechanism in Alzheimer’s Disease: Therapeutic Insights from Schiff Base Derivatives

Abdullah, S., See-Too, W. S., Mohidin, T. B. M., & Mohan, G. (2026) · Molecules · doi:10.3390/molecules31030465 · Cited by 4 · see citing works

An organotin indomethacin derivative inhibits cancer cell proliferation and synergizes the antiproliferative effects of lapatinib in breast cancer cells.

Mendoza, M. S., Camacho-Camacho, C., Rojas‐Oviedo, I., Prado-Garcı́a, H., Barrera, D., Martínez-Reza, I., Larrea, F., & Garcı́a-Becerra, R. (2020) · PubMed Central · Cited by 4 · see citing works

Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease

Fetoh, M. E. A., Abdel‐Fattah, M. M., Afify, H., Ramadan, L. A. A., & Mohamed, W. R. (2023) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_52_23 · Cited by 4 · see citing works

A pharmacokinetic study on lapatinib in type 2 diabetic rats

Karbownik, A., Szałek, E., Sobańska, K., Klupczyńska, A., Plewa, S., Grabowski, T., Wolc, A., Moch, M., Kokot, Z. J., & Grześkowiak, E. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.09.003 · Cited by 4 · see citing works

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies

Lynce, F. C., Wang, H., Petricoin, E. F., Pohlmann, P. R., Smaglo, B. G., Hwang, J. J., He, A. R., Subramaniam, D. S., Deeken, J. F., Marshall, J. L., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03947-7 · Cited by 4 · see citing works

Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy

Beckwitt, C. H. (2018) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 3 · see citing works

High Grade Meningiomas: Current Therapy Based on Tumor Biology

García-Robledo, J. E., Ordóñez‐Reyes, C., Ruíz-Patiño, A., Muñoz, Á., Arrieta, O. G., Jiménez, E., Hakim, F., Gómez, D., Ramón, J. F., & Cardona, A. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100432 · Cited by 3 · see citing works

Breast Cancer Therapies: A Review

Adebayo, K. S., Ajao, J. J., Oderemi, O. M., & Ughagwu, K. P. (2024) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2024.9.1.53-59 · Cited by 2 · see citing works

HER-2 SMASH

Alandağ, C., Öztürk, A., Yulak, F., İnan, Z. D. Ş., Özkaraca, M., Lacın, B. B., & Altun, A. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04726-9 · Cited by 2 · see citing works

The Potency of 4-Methyl-3-Benzoyl Allylthiourea as Anti-Breast Cancer: Molecular Dynamic Simulation, Cytotoxic Activity and its Selectivity Index

Widiandani, T., Delis, S., Mohammad, R. F. P., Purwanto, B., Siswandono, S., & Ifadotunnikmah, F. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00171 · Cited by 2 · see citing works

Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer

Hsu, J. L., & Hung, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_3 · Cited by 2 · see citing works

scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers

Tian, P., Zheng, J., Qiao, K., Fan, Y., Xu, Y., Wu, T., Chen, S., Zhang, Y., Zhang, B., Ambrogio, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202412419 · Cited by 2 · see citing works

Text-mining-based feature selection for anticancer drug response prediction

Wu, G. C., Zaker, A., Ebrahimi, A., Tripathi, S., & Mer, A. S. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae047 · Cited by 1 · see citing works

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?

Tanios, G. E., Burow, M. E., Collins‐Burow, B. M., & Morrison, D. G. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_1 · Cited by 1 · see citing works

Development and Validation of a Multi-Level Computational Protocol for Drug Repurposing in the Treatment of Bacterial Infections

Vieira, T. F., Magalhães, R. P., & Sousa, S. F. (2021) · International Electronic Conference on Synthetic Organic Chemistry (ECSOC) · doi:10.3390/ecsoc-25-11728 · Cited by 1 · see citing works

A review of Lapatinib, a tyrosine kinase inhibitor, in HER2+ metastatic breast cancer treatment development

Huang, A. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/6/20230205 · Cited by 1 · see citing works

Lapatinib-induced PRIDE complex: a new kid on the block

Sil, A., Sikder, B., Biswas, S. K., & Chandra, A. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad064 · Cited by 1 · see citing works

Exploration of crucial stromal risk genes associated with prognostic significance and chemotherapeutic opportunities in invasive ductal breast carcinoma

Tang, G., Wang, Z., Geng, W., Yu, Y., & Zhang, Y. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2024.100448 · Cited by 1 · see citing works

Epigenetic drugs

Cacabelos, R., Naidoo, V., Tellado, I., Corzo, L., Cacabelos, N., Cacabelos, P., Martínez-Iglesias, O. A., & Segre, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00029-3 · Cited by 1 · see citing works

Isolation, Characterization, and Structural Assessment of Novel Isomeric Dimer Impurities Discovered During the Manufacture of Lapatinib Ditosylate Using Preparative HPLC, HRMS, and NMR Techniques

Yerla, R. R., Babu, M. S., Saravanakumar, M., Chormale, S., Krishnamurthy, K. S., & Sunitha, K. (2025) · Separation Science Plus · doi:10.1002/sscp.70101 · Cited by 1 · see citing works

Synergistic inhibition of SCR1- and ERBB2-driven brain metastatic breast cancer cells

Ansari, S. R., Jandial, Z., Wu, X., Liu, X., Chen, M. Y., & Ansari, K. I. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.68 · Cited by 1 · see citing works

Molecular Characterization of Male Breast Cancer

Johansson, I. (2013) · Lund University Publications (Lund University) · Cited by 1 · see citing works

INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA

Saraiva, S., Morgado, S., & Morgado, M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v5i3.44

Paradigme de la prise en charge du cancer bronchique et de celle des autres cancers : homologies, analogies, dissemblances

Pujol, J.-L., Vignot, S., di Mercurio, J.-P., & Quantin, X. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70454-3

O CANCRO DA MAMA METASTIZADO É CURÁVEL? A PROPÓSITO DE UM CASO CLÍNICO

Alexandra, V., & Gomes, R. D. C. (2013)

Fatores prognósticos e preditivos da resposta clínica e patológica em mulheres com carcinoma de mama submetidas a quimioterapia neoadjuvante

Resende, U. (2018) · doi:10.47749/t/unicamp.2018.1009985

Impacto del cambio en la expresión de biomarcadores, utilizados para la clasificación del cáncer de mama en subtipos intrínsecos, asociado al tratamiento neoadyuvante en el pronóstico de mujeres colombianas diagnosticadas en el Instituto Nacional de Cancerología entre los años 2013-2015

Vargas, L. R. (2021) · doi:10.11144/javeriana.10554.52893

Use of peroral form of vinorelbine in metastatic breast cancer – choice in favor of quality of life

Владимировна, Л. Е., Khoroshilov, M. V., Drobot, N. T., & Артамонова, Е. В. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-13-7-13

Nghiên cứu độc tính đơn liều của hạt nano phóng xạ Fe3O4@Lapatinib - 153Sm trên động vật thí nghiệm

Dung, N. T. K., Minh, P. T., Tùng, P. Đ., Thắng, N. Q., Ngoc, H. T., & Sơn, M. H. (2023) · Journal of 108 - Clinical Medicine and Phamarcy · doi:10.52389/ydls.v18iyhhn.1938

Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment

Chae-Eun, Y. A. N. G., Kim, S. B., Jeong, Y., & Lim, J.-Y. (2023) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2023.55.4.298

Lapatinib in breast cancer

Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm220 · Cited by 131 · see citing works

A case report of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy

Meireles, S., da Costa, A. G., Salgado, M., Almeida, D., Pinto, G., & Damasceno, M. (2011) · The Breast · doi:10.1016/j.breast.2011.08.107 · Cited by 1 · see citing works

Lapatinib

(2008) · Springer eBooks · doi:10.1007/978-3-540-47648-1_3277

REVIEW Targeted treatment of advanced and metastatic breast cancer with lapatinib

Corkery, B., & Crown, J. (2013)

Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer

Johnston, S. R. D., & Leary, A. F. (2006) · Drugs of today · doi:10.1358/dot.2006.42.7.985637 · Cited by 174 · see citing works